Testicular Cancer - Global Pipeline Insights, 2022: Featuring Sanofi, Seagen, BioNTech, Context Therapeutics & Leadartis - ResearchAndMarkets.com
Retrieved on:
Wednesday, January 11, 2023
Consumer, Health, Men, Clinical Trials, Oncology, Physical examination, Testicular cancer, News, Prednisone, Ageing, Tubulin, Survival rate, Prognosis, Route, Prostate cancer, Sanofi, European Medicines Agency, Complex, Microtubule, Cell cycle, II, Administration, BioNTech, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cryptorchidism, Discovery, Epidemiology, Interphase, FDA, Cancer, SE, Knowledge, Carlos Roa, CLDN6, Route of administration, CAR, Risk, Metaphase, History, Food, Apoptosis, Therapy, Patient, RNA, Cabazitaxel, Clinical trial, EMA, Docetaxel, Dietary supplement, Vaccine, Pharmaceutical industry, Testicle
This "Testicular Cancer - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Testicular Cancer pipeline landscape.
Key Points:
- This "Testicular Cancer - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Testicular Cancer pipeline landscape.
- Testicular cancer is one of the most common malignancies in men aged 15 to 45 years.
- Complex environmental and genetic factors are involved in the development of testicular cancer; common risk factors include cryptorchidism, family history of testicular cancer, personal history of testicular cancer in the contralateral testis, age, and ethnicity.
- Testicular Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.